190 related articles for article (PubMed ID: 10898536)
1. Cisplatin resistance and oncogenes--a review.
Dempke W; Voigt W; Grothey A; Hill BT; Schmoll HJ
Anticancer Drugs; 2000 Apr; 11(4):225-36. PubMed ID: 10898536
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of resistance to cisplatin.
Kartalou M; Essigmann JM
Mutat Res; 2001 Jul; 478(1-2):23-43. PubMed ID: 11406167
[TBL] [Abstract][Full Text] [Related]
3. Preclinical perspectives on platinum resistance.
Kelland LR
Drugs; 2000; 59 Suppl 4():1-8; discussion 37-8. PubMed ID: 10864225
[TBL] [Abstract][Full Text] [Related]
4. Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells.
Branch P; Masson M; Aquilina G; Bignami M; Karran P
Oncogene; 2000 Jun; 19(28):3138-45. PubMed ID: 10918568
[TBL] [Abstract][Full Text] [Related]
5. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells.
Perego P; Gatti L; Righetti SC; Beretta GL; Carenini N; Corna E; Dal Bo L; Tinelli S; Colangelo D; Leone R; Apostoli P; Lombardi L; Beggiolin G; Piazzoni L; Zunino F
Int J Cancer; 2003 Jul; 105(5):617-24. PubMed ID: 12740909
[TBL] [Abstract][Full Text] [Related]
6. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG
Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864
[TBL] [Abstract][Full Text] [Related]
7. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
O'Neill CF; Koberle B; Masters JR; Kelland LR
Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
[TBL] [Abstract][Full Text] [Related]
8. Screening for modulators of cisplatin sensitivity: unbiased screens reveal common themes.
Nijwening JH; Kuiken HJ; Beijersbergen RL
Cell Cycle; 2011 Feb; 10(3):380-6. PubMed ID: 21239890
[TBL] [Abstract][Full Text] [Related]
9. DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines.
Delmastro DA; Li J; Vaisman A; Solle M; Chaney SG
Cancer Chemother Pharmacol; 1997; 39(3):245-53. PubMed ID: 8996528
[TBL] [Abstract][Full Text] [Related]
10. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression.
Kern MA; Helmbach H; Artuc M; Karmann D; Jurgovsky K; Schadendorf D
Anticancer Res; 1997; 17(6D):4359-70. PubMed ID: 9494534
[TBL] [Abstract][Full Text] [Related]
11. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
12. Decreased drug accumulation and increased tolerance to DNA damage in tumor cells with a low level of cisplatin resistance.
Lanzi C; Perego P; Supino R; Romanelli S; Pensa T; Carenini N; Viano I; Colangelo D; Leone R; Apostoli P; Cassinelli G; Gambetta RA; Zunino F
Biochem Pharmacol; 1998 Apr; 55(8):1247-54. PubMed ID: 9719480
[TBL] [Abstract][Full Text] [Related]
13. Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells.
Materna V; Liedert B; Thomale J; Lage H
Int J Cancer; 2005 Jun; 115(3):393-402. PubMed ID: 15688364
[TBL] [Abstract][Full Text] [Related]
14. Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin.
Kolfschoten GM; Hulscher TM; Schrier SM; van Houten VM; Pinedo HM; Boven E
Gynecol Oncol; 2002 Mar; 84(3):404-12. PubMed ID: 11855878
[TBL] [Abstract][Full Text] [Related]
15. Resistance mechanisms following cisplatin and oxaliplatin treatment of the human teratocarcinoma cell line 2102EP.
Rennicke A; Voigt W; Mueller T; Fruehauf A; Schmoll HJ; Beyer C; Dempke W
Anticancer Res; 2005; 25(2A):1147-55. PubMed ID: 15868958
[TBL] [Abstract][Full Text] [Related]
16. Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis.
Xu ZY; Loignon M; Han FY; Panasci L; Aloyz R
J Pharmacol Exp Ther; 2005 Aug; 314(2):495-505. PubMed ID: 15843498
[TBL] [Abstract][Full Text] [Related]
17. Specificity of platinum-DNA adduct repair.
Chaney SG; Vaisman A
J Inorg Biochem; 1999 Oct; 77(1-2):71-81. PubMed ID: 10626357
[TBL] [Abstract][Full Text] [Related]
18. Preferential repair of the N-ras gene in K 562 cells after exposure to cisplatin.
Dempke W; Voigt W; Grothey A; Schmoll HJ
Anticancer Drugs; 1999 Jul; 10(6):545-9. PubMed ID: 10885902
[TBL] [Abstract][Full Text] [Related]
19. Cellular and molecular determinants of cisplatin resistance.
Perez RP
Eur J Cancer; 1998 Sep; 34(10):1535-42. PubMed ID: 9893624
[TBL] [Abstract][Full Text] [Related]
20. A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system.
Perego P; Caserini C; Gatti L; Carenini N; Romanelli S; Supino R; Colangelo D; Viano I; Leone R; Spinelli S; Pezzoni G; Manzotti C; Farrell N; Zunino F
Mol Pharmacol; 1999 Mar; 55(3):528-34. PubMed ID: 10051537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]